STUDIES ON THE CLINICAL EFFECTS OF AC-1370 TO RTI AND UTI

Abstract

30 patients in total, studied; male 19, female 11, under 59 years old 11, over 60 years old 19 (63.3%); the grades of their infections over moderately 22 (73.3%), the underlying diseases, such as D.M., atrial fibrillation, lung cancer, Wegener's granulomatosis, COLD, lung emphysema, lung tbc, cured, pneumoconiosis, cystlung, bronchiectasis, cerebrovascular disease and uterine cancer, were treated with new antibiotics AC-1370, exploited by Ajinomoto and Mochida pharmaceutical Co.
AC-1370 was given 1.0 g one time, usually two times a day intravenously, duration 7 to 30 days, average 14.2 days, total doses, used, 7 to 60 g, average 28 g, clinical effects: excellent 5, good 22, (90.0%). Bacteriological findings before AC-1370 treatments were 17 strains, including Ps. aeruginosa and K. pneumoniae each 4 strains, S. marcescens 2 strains, Pr. morganii, Ps. putida, Str. pneumoniae, Str. salivarius, A. xylosoxidans, α-Streptococcus and Micrococcus, each one strain and their AC-1370 treatments after, eradicated 7 (41.2%), decreased 3 (17.6%), replaced 5 (29.4%), unchanged 2 (11.8%). Side effects: one patient showed temporary skin rash with the slight elevations of S-GOT and S-GPT, one patient showed slight temporally elevation of S-GPT, and three slight temporally eosinophilias.